NCT03731390Unknown1 期
A Phase I Clinical Study for Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Repeated Doses, Dose Escalation of GR1405 Injection in Patients With Advanced Solid Tumor or Lymphoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- Maximum tolerated dose (MTD)
研究概览
简要总结
This is a Phase I clinical study for evaluating the safety, pharmacokinetics, and preliminary efficacy of repeated doses, dose escalation of GR1405 injection in patients with advanced solid tumor or lymphoma
详细描述
To evaluate the tolerability, safety, pharmacokinetics, and preliminary efficacy of GR1405 injection monotherapy in an open, non-controlled, escalating trial design in patients with advanced solid tumors or lymphomas. Four dose levels (3 mg/kg, 10 mg/kg, 20 mg/kg, and 30 mg/kg) were evaluated at this stage.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with local advanced, recurrent or metastatic solid tumors confirmed by cytology or histology Lymphoma patients with pathological confirmation, and the above pat reients failed to standard treatment failure or had no standard treatment;
- •Aged 18 to 75 years men and women;
- •At least one measurable or evaluable lesion according to Response Evaluation Criteria in Solid Tumors v1.1(RECIST v1.1 )(solid tumor) or Lugano 2014 criteria (lymphoma);
- •Eastern Cooperative Oncology Group(ECOG)≤ 1
- •Female or male subjects of reproductive age and their mate are willing to take effective contraceptive measures for the entire treatment period and 6 months after the treatment;
- •With sufficient organ and bone marrow function;
- •At least 4 weeks after the last anti-tumor treatment before the first administration;
- •The patient or his legal representative signs a written informed consent.
排除标准
- •Have experienced any National Cancer Institute Common Terminology Criteria for Adverse events (NCI CTCAE) v4.03 or greater than 3 grade irAE during previous immunotherapy treatment;
- •Has received any anti-PD-1(programmed death 1) or anti-PD-L1 antibody treatment;
- •Subjects with other malignant tumors previously or concurrently ;
- •Female patients with pregnancy or lactation;
- •Women/men who have fertility refusal to adopt contraception during the trial period;
- •Subjects with serious disease or complications, such as gastrointestinal bleeding, intestinal obstruction, intestinal paralysis, interstitial pneumonia, pulmonary fibrosis, renal failure, glaucoma, uncontrolled diabetes (CTCAE= 4.03: fasting blood glucose level ≥ 2), and with active infection;
- •Had history of acute myocardial infarction, unstable angina pectoris, stroke or transient ischemic attack 6 months before the screening ,grade 2 or above congestive heart failure devised by the New York Heart Association (NYHA);
- •Subjects with symptomatic brain metastases or mental disorders;
- •Subjects with abnormal levels of serum calcium, magnesium, potassium and have clinical significance;
- •Subjects with history of immunodeficiency, including human immunodeficiency virus(HIV)-positive, suffering from other acquired, congenital immunodeficiency disease, or history of organ transplantation;
- •Subjects with active hepatitis B (HBsAg and/or HBcAb positive, and HBV DNA titer in peripheral blood was greater than 1 x 103 IU/ml), and/or hepatitis C;
- •Subjects who have alcohol addiction and/or drug abuse;
- •Subjects with bleeding or coagulation dysfunction in the past 3 months (Prothrombin time(PT)>1.5×upper limit of normal(ULN); activated partial thromboplastin time(APTT)>1.5×ULN; thrombin time(TT)>1.5×ULN);
- •Subjects with allergic constitution or allergic to known components of the drug;
- •Those who received other clinical trial drug therapy within 1 month before the first administration;
- •Receive a live attenuated vaccine within 4 weeks prior to the first dose of study treatment or during the study period;
- •Other subjects judged by the investigator to be ineligible for enrollment in the study.
研究组 & 干预措施
GR1405 injection 3 mg/kg
Experimental
According to the patient's weight, the dose of this group is 3mg/kg.
干预措施: GR1405 injection (Drug)
GR1405 injection 10 mg/kg
Experimental
According to the patient's weight, the dose of this group is 10mg/kg.
干预措施: GR1405 injection (Drug)
GR1405 injection 20 mg/kg
Experimental
According to the patient's weight, the dose of this group is 20mg/kg.
干预措施: GR1405 injection (Drug)
GR1405 injection 30 mg/kg
Experimental
According to the patient's weight, the dose of this group is 30mg/kg.
干预措施: GR1405 injection (Drug)
结局指标
主要结局
Maximum tolerated dose (MTD)
时间窗: 2 weeks
Maximum tolerated dose of GR1405 injection
Adverse Events
时间窗: Approximately 3 years
Number of Participants With Treatment-Emergent Adverse Events as Assessed by CTCAE v4.03
次要结局
- clearance(CL)(Approximately 2 years)
- Duration of response (DOR)(Approximately 3 years)
- Objective Response Rate(ORR)(Approximately 3 years)
- Recommended dose for Phase II trial(RP2D)(Approximately 3 years)
- apparent volume of distribution (Vz)(Approximately 2 years)
- Progression free survival(PFS)(Approximately 3 years)
- t 1/2(Approximately 2 years)
- maximum concentration (Cmax)(Approximately 2 years)
- Immunogenicity(Approximately 3 years)
- AUC0-t(Approximately 2 years)
- AUCss(Approximately 2 years)
- AUC0-∞(Approximately 2 years)
- T max(Approximately 2 years)
研究者
Shi Yuankai
Vice-president
Chinese Academy of Medical Sciences
研究点 (1)
Loading locations...
相似试验
尚未招募
1 期
F01 in the Treatment of Moderate-to-severe Refractory Systemic Lupus ErythematosusLupus ErythematosisNCT06468683Shanghai Simnova Biotechnology Co.,Ltd.50
Unknown
1 期
A Phase 1 Study to Evaluate JS019 in Advanced Solid Tumors or LymphomasAdvanced Solid Tumors or LymphomasNCT05374226Suzhou Kebo Ruijun Biotechnology Co., Ltd172
Unknown
1 期
A Clinical Study to Evaluate the Safety, Tolerability,JS019 in Patients With Advanced Solid TumorsAdvanced Solid TumorsNCT05508373Suzhou Kebo Ruijun Biotechnology Co., Ltd72
招募中
1 期
A Phase 1 Study of BB102 in Participants With Advanced Solid TumorsAdvanced Solid TumorNCT06258408Broadenbio Ltd., Co.78
招募中
1 期
BC008-1A Injection for Recurrent CNS WHO G4 GliomaGlioma Tumor RecurrenceGlioma, Recurrent High GradeGlioblastomas (GBM)Glioblastoma WHO Grade IVGliomaNCT06773481Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd.40